BBOT
BridgeBio Oncology Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
BridgeBio Oncology Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Fund move
Fund move
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Linked news
BridgeBio Oncology Therapeutics, Inc.
2.31
0.00 · −0.16%
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Cormorant Asset ManagementCormorant | $136.2M | 30.24% | 0.00% | |
| 2 | Deerfield ManagementDeerfield | $37.2M | 8.26% | 0.00% | |
| 3 | Omega Fund ManagementOmega Fund | $25.1M | 5.56% | 0.00% | |
| 4 | EcoR1 CapitalEcoR1 Capital | $21.5M | 4.77% | 0.00% | |
| 5 | AlphabetAlphabet | $21.5M | 4.77% | 0.00% | |
| 6 | Wellington Management GroupWellington | $21.3M | 4.72% | −1.03% | |
| 7 | Enavate Sciences GPEnavate Sciences GP | $20.0M | 4.44% | 0.00% | |
| 8 | Citadel AdvisorsCitadel | $19.9M | 4.43% | +3.52% | |
| 9 | NovoNovo | $17.1M | 3.81% | +2.93% | |
| 10 | BlackRockBlackRockindex-like | $16.4M | 3.64% | +3.15% | |
| 11 | Vanguard Capital ManagementVanguardindex-like | $15.3M | 3.39% | +272.49% | |
| 12 | Laurion Capital ManagementLaurion | $15.3M | 3.39% | +4.16% | |
| 13 | Armistice CapitalArmistice Capital | $13.4M | 2.98% | +32.83% | |
| 14 | State StreetState Streetindex-like | $7.9M | 1.75% | +358.10% | |
| 15 | Aisling Capital ManagementAisling | $7.8M | 1.72% | 0.00% | |
| 16 | Opaleye ManagementOpaleye | $5.3M | 1.18% | +1213.76% | |
| 17 | Geode Capital ManagementGeodeindex-like | $4.7M | 1.05% | +7.44% | |
| 18 | Granahan Investment ManagementGranahan | $4.3M | 0.94% | +141.74% | |
| 19 | Sphera Funds ManagementSphera Funds | $3.5M | 0.78% | new | |
| 20 | Adage Capital Partners GPAdage Capital Partners GP | $3.0M | 0.68% | 0.00% | |
| 21 | Royce & AssociatesRoyce & | $2.9M | 0.65% | −39.52% | |
| 22 | Catalio Capital ManagementCatalio | $2.4M | 0.54% | new | |
| 23 | T. Rowe Price AssociatesT. Rowe Price | $2.3M | 0.51% | −31.49% | |
| 24 | Vanguard Fiduciary TrustVanguard Fiduciary Trustindex-like | $2.2M | 0.49% | +14.62% | |
| 25 | Charles Schwab Investment ManagementCharles Schwabindex-like | $2.2M | 0.48% | −1.47% |
65 managers report $450.6M of BridgeBio Oncology Therapeutics on form 13F for the quarter ended Jun 30 '26. 12 of them hold 80% of it; Cormorant is largest at 30.24%.
Expected move
No implied move.
No implied move.
No implied move.